Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sofinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 20/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 20/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sofinicline SCHEMBL650489 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL650490 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL4436795 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL22754711 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL1560706 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL5096637 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL5929684 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL5929688 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL3913110 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Sofinicline SCHEMBL2080581 | 0.92 | CHRNB2 (0.85) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | claimed |
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | claimed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | claimed |
| US-20140121193-A1 | METHODS FOR TREATING FIBROMYALGIA | KATZ ROBERT S (US) | 2014-05-01 | — | — | US | claimed |
| EP-2489353-A1 | Sofinicline (ABT-894) for attention-deficit/hyperactivity disorder | Abbott Laboratories (US) | 2012-08-22 | — | — | EP | claimed |
| US-8222278-B2 | Treatment of attention-deficit/hyperactivity disorder | ABBOTT LABORATORIES (US) | 2012-07-17 | — | — | US | claimed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | claimed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| US-7354937-B2 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane | ABBOTT LABORATORIES (US) | 2008-04-08 | — | — | US | claimed |
| US-20080070891-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBVIE INC. | 2008-03-20 | — | — | US | claimed |
| US-20080004448-A1 | (1S,5S)-3-(5.6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBVIE INC. | 2008-01-03 | — | — | US | claimed |
| US-20060035936-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | ABBVIE INC. | 2006-02-16 | — | — | US | claimed |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBVIE INC. | 2006-02-16 | — | — | US | claimed |
| US-20050261348-A1 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | claimed |
| US-20040242641-A1 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | claimed |
| US-20040242644-A1 | (IS-5S)-3-(5,6-dichloro-3-pyridinyl-)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | claimed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | DHPS, HCN2, DCPS | CHRNB2 2936/4885CHRNA4 2769/4885CHRNB4 3327/4885 |
| US-20080004448-A1 | (1S,5S)-3-(5.6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | DHPS, HCN2, DCPS | CHRNB2 2933/4885CHRNA4 2761/4885CHRNB4 3314/4885 |
| US-20240173318-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885CHRNB4 1806/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | CHRNB2 8/4885CHRNA4 9/4885CHRNB4 11/4885 |
| US-20080070891-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | CHRNA6, CHRNA5, CHRNA3 | CHRNB2 12/4885CHRNA4 7/4885CHRNB4 17/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20060035936-A1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE | CHRNA6, CHRNA5, CHRNA3 | CHRNB2 12/4885CHRNA4 7/4885CHRNB4 17/4885 |
| US-20140121193-A1 | METHODS FOR TREATING FIBROMYALGIA | HTR5A, COMT, HTR4 | CHRNB2 265/4885CHRNA4 51/4885CHRNB4 118/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | CHRNB2 5/4885CHRNA4 1/4885CHRNB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.